MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Faricimab

  • Home
  • Faricimab
Predictive Value of Early Fluid Resolution for Long-term Durability of Faricimab in Neovascular Age-Related Macular Degeneration: A Synthesis of Evidence
Posted inClinical Updates news Ophthalmology

Predictive Value of Early Fluid Resolution for Long-term Durability of Faricimab in Neovascular Age-Related Macular Degeneration: A Synthesis of Evidence

Posted by By MedXY 03/24/2026
This review synthesizes clinical trial data demonstrating that rapid resolution of retinal fluid by week 12 with faricimab significantly predicts long-term treatment durability in patients with neovascular age-related macular degeneration.
Read More
Rapid Fluid Resolution with Faricimab Predicts Long-Term Treatment Durability in nAMD
Posted innews Ophthalmology

Rapid Fluid Resolution with Faricimab Predicts Long-Term Treatment Durability in nAMD

Posted by By MedXY 02/19/2026
A post hoc analysis of the TENAYA and LUCERNE trials demonstrates that early resolution of retinal fluid by week 12 with faricimab is a significant predictor of achieving extended every-16-week dosing intervals in patients with neovascular age-related macular degeneration.
Read More
  • Evaluating the Specificity of Capillary Leak Indices in Heart Failure: Implications for Clinical Practice
  • Unveiling Non-Genetic Influences on Hereditary Ataxia: Insights from SCA6 and SCA27B Cohorts
  • Enhancing Parathyroid Gland Preservation in Total Thyroidectomy: Efficacy of Near-Infrared Autofluorescence Probe (PTeye) Versus Visual Identification
  • Long-Term Survival Benefit of Daratumumab with Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Insights from the MAIA Final Analysis
  • Cascade Genetic Screening in Hereditary Transthyretin Amyloidosis: Unlocking Earlier Diagnosis and Improved Outcomes
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top